These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38739102)

  • 1. Enhanced systemic antitumor efficacy of PD-1/PD-L1 blockade with immunological response induced by photodynamic therapy.
    Sonokawa T; Fujiwara Y; Pan C; Komohara Y; Usuda J
    Thorac Cancer; 2024 Jun; 15(18):1429-1436. PubMed ID: 38739102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
    Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of a novel heat shock protein 90-targeted photodynamic therapy with PD-1/PD-L1 blockade induces potent systemic antitumor efficacy and abscopal effect against breast cancers.
    Kaneko K; Acharya CR; Nagata H; Yang X; Hartman ZC; Hobeika A; Hughes PF; Haystead TAJ; Morse MA; Lyerly HK; Osada T
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36171008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 blockade potentiates the antitumor effects of ALA-PDT and optimizes the tumor microenvironment in cutaneous squamous cell carcinoma.
    Zeng Q; Yang J; Ji J; Wang P; Zhang L; Yan G; Wu Y; Chen Q; Liu J; Zhang G; Wang X
    Oncoimmunology; 2022; 11(1):2061396. PubMed ID: 35402079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing Anti-PD-1/PD-L1 Immune Checkpoint Inhibitory Cancer Therapy by CD276-Targeted Photodynamic Ablation of Tumor Cells and Tumor Vasculature.
    Bao R; Wang Y; Lai J; Zhu H; Zhao Y; Li S; Li N; Huang J; Yang Z; Wang F; Liu Z
    Mol Pharm; 2019 Jan; 16(1):339-348. PubMed ID: 30452269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chlorin e6-associated photodynamic therapy enhances abscopal antitumor effects via inhibition of PD-1/PD-L1 immune checkpoint.
    Gurung P; Lim J; Shrestha R; Kim YW
    Sci Rep; 2023 Mar; 13(1):4647. PubMed ID: 36944686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of PD-1/PD-L1 Pathway Enhances the Antigen-Presenting Capacity of Fibrocytes.
    Afroj T; Mitsuhashi A; Ogino H; Saijo A; Otsuka K; Yoneda H; Tobiume M; Nguyen NT; Goto H; Koyama K; Sugimoto M; Kondoh O; Nokihara H; Nishioka Y
    J Immunol; 2021 Mar; 206(6):1204-1214. PubMed ID: 33504617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic Antitumor Immunity by PD-1/PD-L1 Inhibition Is Potentiated by Vascular-Targeted Photodynamic Therapy of Primary Tumors.
    O'Shaughnessy MJ; Murray KS; La Rosa SP; Budhu S; Merghoub T; Somma A; Monette S; Kim K; Corradi RB; Scherz A; Coleman JA
    Clin Cancer Res; 2018 Feb; 24(3):592-599. PubMed ID: 28954788
    [No Abstract]   [Full Text] [Related]  

  • 10. Photodynamic therapy synergizes with PD-L1 checkpoint blockade for immunotherapy of CRC by multifunctional nanoparticles.
    Yuan Z; Fan G; Wu H; Liu C; Zhan Y; Qiu Y; Shou C; Gao F; Zhang J; Yin P; Xu K
    Mol Ther; 2021 Oct; 29(10):2931-2948. PubMed ID: 34023507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
    Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models.
    Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL
    J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal.
    Wang Z; Chen L; Ma Y; Li X; Hu A; Wang H; Wang W; Li X; Tian B; Dong J
    J Nanobiotechnology; 2021 Aug; 19(1):243. PubMed ID: 34384429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of Photodynamic Therapy and a Flagellin-Adjuvanted Cancer Vaccine Potentiated the Anti-PD-1-Mediated Melanoma Suppression.
    Hwang HS; Cherukula K; Bang YJ; Vijayan V; Moon MJ; Thiruppathi J; Puth S; Jeong YY; Park IK; Lee SE; Rhee JH
    Cells; 2020 Nov; 9(11):. PubMed ID: 33171765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential and unsolved problems of anti-PD-1/PD-L1 therapy combined with radiotherapy.
    Cao Y; Li W; Wang Z; Pang H
    Tumori; 2021 Aug; 107(4):282-291. PubMed ID: 32734832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GSH-responsive polymeric micelles-based augmented photoimmunotherapy synergized with PD-1 blockade for eliciting robust antitumor immunity against colon tumor.
    Huang C; Yang X; Li H; Zhang L; Guo Q; Yu Q; Wang H; Zhang L; Zhu D
    J Nanobiotechnology; 2024 Sep; 22(1):542. PubMed ID: 39238020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PAK1 inhibition increases TRIM21-induced PD-L1 degradation and enhances responses to anti-PD-1 therapy in pancreatic cancer.
    Wang K; Yan L; Qiu X; Chen H; Gao F; Ge W; Lian Z; Wei X; Wang S; He H; Xu X
    Biochim Biophys Acta Mol Basis Dis; 2024 Aug; 1870(6):167236. PubMed ID: 38740225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic virus oHSV2 combined with PD-1/PD-L1 inhibitors exert antitumor activity by mediating CD4 + T and CD8 + T cell infiltration in the lymphoma tumor microenvironment.
    Zhang J; Guo Y; Fang H; Guo X; Zhao L
    Autoimmunity; 2023 Dec; 56(1):2259126. PubMed ID: 37736847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.
    Zeng Y; Li B; Liang Y; Reeves PM; Qu X; Ran C; Liu Q; Callahan MV; Sluder AE; Gelfand JA; Chen H; Poznansky MC
    FASEB J; 2019 May; 33(5):6596-6608. PubMed ID: 30802149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mild hyperthermia upregulates PD-L1 in the tumor microenvironment and enhances antitumor efficacy of PD-L1 blockade in murine squamous cell carcinoma.
    Ohta Y; Ichimura N; Yamaguchi S; Ohara G; Yamamoto N; Itoh Y; Yamada K; Nakamura S; Hibi H
    Nagoya J Med Sci; 2024 Aug; 86(3):497-506. PubMed ID: 39355357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.